Wei Jia, Chen Yan
Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China.
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008 Dec;16(6):1465-72.
Myelodysplastic syndrome (MDS) represents a heterogeneous group of myeloid malignancies characterized by abnormal differentiation and maturation of myeloid cells, bone marrow failure, and a genetic instability with enhanced risk to transform to acute myeloid leukemia. Many factors influence on the prognosis of MDS. The prognosis of MDS subtypes has been changing with the application of World Health Organization (WHO) classification and different new prognostic scoring system, the technology development of cytogenetics and flow cytometry, and the advent of new drugs. A series of recent literatures are summarized on different prognostic factors of MDS. In this review, the controversy in application of WHO classification, MDS prognosis in relation with prognostic scoring system, cytogenetics, immunophenotype and therapeutics were discussed.
骨髓增生异常综合征（MDS）是一组异质性髓系恶性肿瘤，其特征为髓系细胞分化和成熟异常、骨髓衰竭以及具有向急性髓系白血病转化的高风险的基因不稳定性。许多因素影响MDS的预后。随着世界卫生组织（WHO）分类和不同新预后评分系统的应用、细胞遗传学和流式细胞术技术的发展以及新药的出现，MDS各亚型的预后一直在变化。本文总结了一系列关于MDS不同预后因素的近期文献。在这篇综述中，讨论了WHO分类应用中的争议、与预后评分系统相关的MDS预后、细胞遗传学、免疫表型和治疗方法。
